Catherine Sims, ACR 2022: Impact of the HOP-STEP intervention in women with systemic lupus erythematosus
In women with systemic lupus erythematosus (SLE), ill-timed pregnancies can cause complications related to teratogen use and SLE activity. In this touchIMMUNOLOGY interview we spoke with Dr. Catherine Sims (Duke University, Durham, NC, USA) around her study implementing the HOP-STEP intervention to promote well-timed pregnancies in women with SLE, and the impact of the HOP-STEP pregnancy planning discussions on pregnancy complications.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘The Impact of Pregnancy Planning and Medical Readiness on Reproductive Outcomes in Women with SLE.‘ (Abstract number: 0946) was presented at the ACR Convergence, November 10–14, 2022.
- What are the challenges of the current recommendations of the ACR Reproductive Health Guidelines for women with systemic lupus erythematosus (SLE) in planning pregnancy? (0:14)
- What is the HOP-STEP intervention? (1:27)
- What were the aims and design of your SLE registry study? (3:06)
- What was the impact of the HOP-STEP pregnancy planning discussions on pregnancy complications? (4:00)
- What are the key take-home messages of this study? (4:59)
Disclosures: Catherine Sims discloses grant/research support from UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Systemic Lupus Erythematosus
Kevin Winthrop, ACR 2022: Anifrolumab for systemic lupus erythematosus – safety findings from the 3-year TULIP extension study
TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) were phase 3, randomized, double-blind, placebo-controlled trials that investigated the efficacy and safety of anifrolumab, a fully human IgG1 κ monoclonal antibody, in the treatment of systemic lupus erythematosus. In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to learn more about […]
Victoria P. Werth, ACR 2022: Findings from the phase 2 LILAC study of BIIB059 in cutaneous lupus erythematosus
Part B of the phase 2 LILAC study (NCT02847598) investigated BIIB059, a humanized monoclonal antibody against BDCA2, for the treatment of cutaneous lupus erythematosus (CLE). In this touchIMMUNOLOGY interview, we were delighted to speak with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) around the unmet needs in the treatment of CLE, the […]
Jorge Sanchez-Guerrero, ACR 2022: Belimumab for mucocutaneous manifestations of systemic lupus erythematosus – findings from a pooled post hoc analysis
Mucocutaneous manifestations affect over 80% of patients with systemic lupus erythematosus (SLE) and can significantly impact on patient quality of life. touchIMMUNOLOGY were delighted to speak with Prof. Jorge Sanchez-Guerrero (University of Toronto, Toronto, ON, Canada) around his post hoc analysis investigating the effects of belimumab on the mucocutaneous manifestations of SLE. This information is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!